Study identifier:LAS-MD-CL26
ClinicalTrials.gov identifier:NCT00500318
EudraCT identifier:N/A
CTIS identifier:N/A
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 6-Week Clinical Study to Assess the Effect of Inhaled Aclidinium Bromide (LAS34273) 200 ug on Exercise Endurance and Lung Hyperinflation in Patients with Moderate to Severe COPD
Pulmonary Disease, Chronic Obstructive
Phase 3
No
Aclidinium Bromide, Placebo
All
181
Interventional
40 Years +
Allocation: Randomized
Endpoint Classification: None
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Nov 2016 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Aclidinium | Drug: Aclidinium Bromide Aclidinium Bromide, 200μg. Once daily oral inhalation. |
Placebo Comparator: Placebo | Drug: Placebo Dose matched placebo, once daily oral inhalation. |